Message from the Guest Editors

Dear Colleagues,

Molecular technology platforms have exponentially developed to a status where individual patient-acquired pathologies can be profiled at various levels. Where does the technology meet unmet clinical needs?

In this Special Issue, we invite you to submit manuscripts that illustrate the clinical utility and impact of molecular research into clinical urological practice. We invite both oncological, as well as non-oncological papers. Topics to be considered include, but are not limited to, precision medicine in GU oncology, new molecular therapeutical targets, biomarkers for non-oncological bladder disease, and advances in molecular tissue engineering.

Prof. Dr. Jack A. Schalken
Prof Dr. Natasha Kyprianou
Guest Editors

Author Benefits

Open Access: free for readers, with publishing fees paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science), MEDLINE (PubMed) and other databases.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 22 days after submission; acceptance to publication is undertaken in 8 days (median values for 2016).